We scan new podcasts and send you the top 5 insights daily.
Next-generation dual-payload ADCs combine distinct mechanisms, such as microtubule inhibitors with topoisomerase I inhibitors or ATR inhibitors, effectively acting as targeted combination chemotherapy. Dr. Liu notes their success will depend heavily on whether efficacy outweighs toxicities caused by free payloads circulating systemically.
Dr. Liu highlights that sequentially administering ADCs remains active if clinicians change the cytotoxic payload, even when targeting the identical receptor. Conversely, emerging prospective breast cancer trials indicate that sequencing a topoisomerase I inhibitor ADC directly after another yields very low antitumor response rates.
To combat payload-related resistance, clinicians are reluctant to use two ADCs with the same payload (e.g., a deruxtecan) consecutively. The preferred strategy is to 'sandwich' a different class of chemotherapy between the two ADCs, hoping to restore sensitivity to the payload.
The modern pipeline of antibody-drug conjugates in solid tumors has largely moved away from older microtubule toxin payloads (like DM4 or MMAE). The majority of ADCs currently in development, and the focus of clinical excitement, utilize camptothecin-based payloads, specifically topoisomerase-1 inhibitors like deruxtecan, reflecting a major technological evolution in the field.
With multiple ADCs available, an emerging sequencing strategy is to alternate between different mechanisms of action, such as following a microtubule toxin-based ADC with a topoisomerase-1 inhibitor payload. This approach aims to avoid compounding specific toxicities, like neuropathy, and potentially circumvent resistance, though it is a strategy born from logic rather than clinical trial data.
When sequencing antibody-drug conjugates (ADCs), the critical factor for efficacy may not be switching the antibody target, but rather switching the cytotoxic payload. For example, using an ADC with a different payload (like tizotumab vedotin’s MMAE) after one with a topoisomerase inhibitor (like TDXD) could overcome resistance, shifting the paradigm from 'ADC after ADC' to 'payload after payload'.
The primary reason Antibody-Drug Conjugates (ADCs) stop working is payload resistance, a shift from the traditional belief that failure stems from tumors losing the target antigen. This insight drives development of multi-payload ADCs to overcome this resistance mechanism.
When planning treatment for patients who will receive multiple antibody-drug conjugates (ADCs), the prevailing clinical strategy is to focus on alternating the drug's payload (e.g., a tubulin inhibitor vs. a topoisomerase I inhibitor). This approach is believed to be more effective at overcoming resistance than alternating the cell-surface target.
A promising future strategy for ovarian cancer involves combining two different ADCs. The key to this approach is selecting agents with distinct payloads (e.g., an anti-microtubulin and a TOPA-1 inhibitor) whose side effect profiles do not overlap. This could maximize anti-tumor efficacy while maintaining a manageable toxicity burden for patients, offering a novel combination paradigm.
As more antibody-drug conjugates (ADCs) become available, a key concern is resistance to the cytotoxic payload. If a tumor develops resistance to a topoisomerase-1 inhibitor from one ADC, it may not respond to other ADCs using the same payload, regardless of their different antibody targets, complicating future treatment sequencing.
In the absence of definitive data, a practical strategy is emerging to alternate ADC payloads, such as switching from a microtubule toxin to a topoisomerase inhibitor. This approach aims to avoid compounding toxicities like neuropathy and potentially circumvent drug resistance mechanisms.